Results 21 to 30 of about 38,148 (251)
Focusing on quality patient care in the new global subsidy for malaria medicines. [PDF]
, 2009 Tido von Schoen-Angerer and colleagues discuss the new Affordable Medicines Facility for malaria (AMFm), which subsidizes and facilitates access to artemisinin-based combination therapy, and what mechanisms are needed to ensure it stays focused on ...
Moon, S +4 more
core +2 more sources
Biomédica: revista del Instituto Nacional de Salud, 2008 Introducción. Los estudios de susceptibilidad in vitro de Plasmodium falciparum a los medicamentos antipalúdicos son herramientas importantes para vigilar la utilidad de esos medicamentos; tales estudios son escasos en Colombia. Objetivo.
Silvia Blair +2 more
doaj +1 more source
Frontiers in Drug Discovery, 2023 More than sesquicentennial years of malarial research, however the unique malarial parasite, Plasmodium still bewilders us with its atypical characteristic features.
Ankita Tehlan +3 more
doaj +1 more source
Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance [PDF]
, 2013 The biggest threat to the war on malaria is the continued evolution of drug resistance by the parasite. Resistance to almost all currently available antimalarials now exists in Plasmodium falciparum which causes the most suffering among all human malaria
Mwangi, J.M., Ranford-Cartwright, L.C.
core +1 more source
Malaria: The Past and the Present
Microorganisms, 2019 Malaria is a severe disease caused by parasites of the genus Plasmodium, which is transmitted to humans by a bite of an infected female mosquito of the species Anopheles.
Jasminka Talapko +4 more
doaj +1 more source
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. [PDF]
, 2005 Highly active antiretroviral therapy has substantially improved prognosis in human immunodeficiency virus (HIV). However, the integration of proviral DNA, development of viral resistance, and lack of permeability of drugs into sanctuary sites (e.g ...
Back, DJ +9 more
core +1 more source
Infection and Drug Resistance, 2022 Tamirat Tekassa,1 Gemmechu Hasen,1 Hailu Merga,2 Anne-Laure Cavin,3 Bertrand Graz,3 Sultan Suleman1 1School of Pharmacy, Institute of Health, Jimma University, Jimma, Oromia Regional State, Ethiopia; 2Department of Epidemiology, Institute of Health ...
Tekassa T +5 more
doaj
Adherence to a Six-Dose Regimen of Artemether-Lumefantrine for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Uganda. [PDF]
, 2004 Measuring baseline levels of adherence and identifying risk factors for non-adherence are important steps before the introduction of new antimalarials. In Mbarara in southwestern Uganda, we assessed adherence to artemether-lumefantrine (Coartem) in its ...
Bajunirwe, F +9 more
core +2 more sources
Impact of Drug Pressure versus Limited Access to Drug in Malaria Control: The Dilemma
Medicines, 2022 Malaria burden has severe impact on the world. Several arsenals, including the use of antimalarials, are in place to curb the malaria burden. However, the application of these antimalarials has two extremes, limited access to drug and drug pressure ...
Chinedu Ogbonnia Egwu +6 more
doaj +1 more source
The Trypanosoma cruzi enzyme TcGPXI is a glycosomal peroxidase and can be linked to trypanothione reduction by glutathione or tryparedoxin. [PDF]
, 2002 Trypanosoma cruzi glutathione-dependent peroxidase I (TcGPXI) can reduce fatty acid, phospholipid, and short chain organic hydroperoxides utilizing a novel redox cycle in which enzyme activity is linked to the reduction of trypanothione, a parasite ...
Docampo +56 more
core +3 more sources